The 6 conditions that ride shotgun with PCOS, and why treating them together matters
PCOS is a systemic condition, not only a gynecological one. Its metabolic, cardiovascular, psychological and reproductive dimensions overlap with several other conditions that share the underlying pathophysiology. Missing these comorbidities means treating symptoms while the root drivers of long-term risk continue unchecked.
PCOS rarely travels alone
PCOS affects the ovaries, but the underlying hormonal and metabolic dysfunction touches every system. Treating PCOS in isolation while missing these comorbidities usually underdelivers on outcomes. Key figures:
- 34% of PCOS women have depression
- 3 times higher anxiety than controls
- 4-5 times lifetime type 2 diabetes risk
- 2 times cardiovascular mortality
- 3 times endometrial cancer risk from chronic anovulation
- About 40% have fatty liver (NAFLD)
Prevalence figures from Cooney LG meta-analysis on depression (Human Reproduction 2017), Rubin KH nationwide PCOS T2DM study (JCEM 2017), Zhu T PCOS CV outcomes (Diabetes 2021), Barry JA endometrial cancer meta-analysis (Human Reproduction Update 2014).
1. Type 2 diabetes and insulin resistance
PCOS women have 4-5 times the lifetime T2DM risk (Rubin 2017). Insulin resistance is present in 50-70% of PCOS regardless of BMI. Annual glucose screening (HbA1c or OGTT) is recommended from PCOS diagnosis. Metformin and lifestyle intervention substantially reduce progression to T2DM.
2. Depression and anxiety
Depression prevalence in PCOS is 3-4 times that of age-matched controls (Cooney 2017 meta-analysis, 34% of PCOS women). Anxiety prevalence is about 3 times higher. Body image, fertility struggles and PCOS-specific distress contribute. CBT + SSRIs when needed, coordinated with your gynecologist.
3. Cardiovascular disease risk
PCOS women have 2 times the cardiovascular mortality risk (Zhu 2019 meta-analysis). Contributors: insulin resistance, dyslipidemia, hypertension, inflammation, obesity. Annual BP + lipid panel from PCOS diagnosis. Statin therapy per usual criteria. Aggressive lifestyle intervention.
4. Endometrial cancer risk
Chronic anovulation leads to unopposed estrogen, then endometrial hyperplasia, and about 3 times the endometrial cancer risk (Barry 2014). It is preventable with regular withdrawal bleeds (COCPs or cyclical progesterone) or continuous progestin (Mirena IUD). Any post-menopausal bleeding, or heavy irregular bleeding in PCOS, needs prompt evaluation.
5. Fatty liver (NAFLD)
Non-alcoholic fatty liver disease prevalence in PCOS is about 40% (vs about 25% in the general population). The shared driver is insulin resistance. Screen with LFTs + fasting glucose annually; ultrasound or FibroScan if ALT is elevated. Weight loss of 7-10% reverses steatosis in most cases.
6. Obstructive sleep apnea
OSA prevalence in obese PCOS is 5-10 times that of age-matched women. It contributes to fatigue, worsens insulin resistance and increases CV risk. STOP-BANG screening; sleep study if positive. CPAP substantially improves insulin sensitivity and quality of life.
One PCOS panel, not six separate appointments
PCOS with T2DM + depression + fertility concerns + hair loss can mean 4 separate specialist visits with no coordination, everyone treating their piece and no one looking at the whole picture. A coordinated plan brings gynecology, endocrinology, dietetics, psychology and dermatology into one shared care plan, with regular touchpoints with a care coordinator and periodic panel reviews.
